Constantine Tam, MD, director, CLL and low-grade lymphoma program, Victorian Comprehensive Cancer Centre, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

The 2 abstracts, presented at the American Society of Hematology (ASH) Annual Meeting, are updated data from 2 studies presented at last year’s ASH. BGB-3111 is very specific in that it hits many BTK targets with very little effect on other off-target enzymes, which allows physicians to give patients higher doses, Tam says. Thus, the drug levels are 8 to 10 levels higher than BTK inhibitor ibrutinib.

Now, the question is since BTK inhibition has been pushed to such a high level, can responses be improved in patients who receive this drug, relative to other drugs on the market, Tam says.

View more from the 2016 ASH Annual Meeting

Videos

 
Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.
 

Constantine Tam, MD

Articles

Dr. Tam on Trials Investigating BGB-3111 in CLL and Waldenstrom's Macroglobulinemia